Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DFP-10917 in relapsed/refractory AML
NCT03926624Phase 3Terminated
- Sponsor
- Delta-Fly Pharma, Inc.
- Start
- Nov 2019
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of radgocitabine in acute myeloid leukemia (AML) (2 arms), sponsored by Delta-Fly Pharma, Inc. Primary endpoints: Complete Remission Rate at 3 years and Duration of Complete Remission at 3 years. Started Nov 2019; status: terminated.
02
Drugs
radgocitabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03926624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03926624.